Actively Recruiting
Evaluating the Safety and Dose of NY-ESO-1 TCRdnTGFRII Engineered T Cells with Decitabine in Treating Recurrent or Resistant Ovarian Cancer and Other Advanced Solid Tumors
Led by University of Chicago · Updated on 2026-10-13
24
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating gene-modified T cells combined with or without decitabine to treat patients with ovarian cancer and other advanced malignant solid tumors expressing cancer-testis antigens. This phase IIIA trial focuses on assessing side effects, determining the best dose, and understanding how well these treatments work in patients with recurrent or treatment-refractory disease. Participants may receive a combination of treatments including decitabine taken orally for 5 days, cyclophosphamide conditioning intravenously for 2 days, the NY-ESO-1 TCRdnTGFRII engineered T cells at varying doses, and aldesleukin given by injection twice daily for 10 days. The study includes sequential enrollment in different arms a lead-in safety cohort, dose adjustment cohort if needed, and expansion cohorts for ovarian cancer and other solid tumors after determining a safe dose. Participants will undergo tissue testing for NY-ESO-1 expression and HLA-A*0201 typing before enrollment. During the study, they will be closely monitored for treatment-related side effects and tumor response using immune-related criteria and standard tumor measurements over up to two years. Assessments include imaging scans, laboratory tests, and clinical exams. Participants must have a caregiver available and arrange transportation during hospitalization and recovery. The study tracks safety and tumor effects with visits scheduled according to treatment and follow-up protocols.
CONDITIONS
Brief Title
A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.
Research Team
C
Clinical Trials Intake Intake
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here